Glaxo: Q3 Earnings Snapshot

GSK reported Q3 2026 earnings, highlighting progress in its oncology pipeline, including approvals for Jideytro, Hibsago, and Jemperli. The company discussed data on Jideytro and neladalkib for non-small cell lung cancer, Ris-Rez for various solid tumors, and Mo-Rez for ovarian cancer. GSK also mentioned its Accelerate Growth program to reallocate resources to R&D and accelerate late-stage development.

GSK reported Q3 earnings, highlighting growth in oncology drugs like Blenrep, Ojjaara, and Jemperli, and new approvals for Jideytro and Hibsago. Vaccine sales declined 2%, while meningitis portfolio rose 12%. GSK launched 18 phase III studies in 2026, with plans for more. Financials showed 7% gross profit increase, stable margins, and £1.8 billion free cash flow rise. The company expects £10 billion in cash from operations for the full year and core operating margin above 31%.

GSK reported a 23% drop in Q3 net profit to £1.5B due to restructuring costs, but revenue rose 4% to £8.9B. The company reaffirmed its full-year guidance, with strong sales in cancer, respiratory, and HIV drugs. CEO Luke Miels emphasized long-term focus on R&D and operational delivery.

GSK's shares fell 4% despite Q3 sales and profit beats, as investors focused on pipeline concerns and weak vaccine sales, including Shingrix. CEO Luke Miels emphasized long-term strategy and R&D focus. Specialty medicine sales rose 15%, but new asthma drug and vaccine revenue missed expectations. GSK maintained annual outlook but expects R&D spending to outpace sales growth. The company is restructuring to fund new medicines, with a £328 million restructuring charge in Q3.

GSK's head of oncology research, Hesham Abdullah, told the WSJ the company aims to nearly double its cancer drug pipeline by 2027, targeting 19-20 late-stage studies. This push is part of CEO Luke Miels' strategy to address patent expirations for HIV drugs. GSK's oncology segment generated £1.08 billion in H1 2026.

Wendy's shares rose 15% to $7.07 after a $7.35/share cash offer. Stellantis shares surged 15% on higher Q3 income and 2027 cash flow target. SK Hynix reported record Q3 revenue of $79B, up 328% YoY. Etsy's Q3 revenue rose 11%, shares up 3.8%. Vertiv raised 2026 forecasts after Q3 revenue beat estimates. GE Vernova's Q3 net income nearly tripled to $1.3B. NXP Semiconductors beat Q3 expectations but shares fell 2.2% on outlook. F5 shares dropped 18% on weaker guidance despite 13% revenue growth.